Drug
Levocarnitine Oral
Important: Reactions below are the flagged terms from this drug’s
FAERS report history (min. 3 co-reports per term) — PRR/ROR indicate
disproportionality in spontaneous reporting, not causation.
Data from FDA FAERS via openFDA. Last recalculated: 2026-09-14.
| Reaction | Co-reports (a) | PRR | ROR | Signal | |
|---|---|---|---|---|---|
| 1 | Status Epilepticus | 35 | 22.2 | 22.4 | signal |
| 2 | Seizure | 288 | 18.0 | 19.8 | signal |
| 3 | Generalised Tonic-clonic Seizure | 31 | 13.6 | 13.7 | signal |
| 4 | Epilepsy | 56 | 13.1 | 13.4 | signal |
| 5 | Hepatic Encephalopathy | 16 | 12.3 | 12.3 | signal |
| 6 | Device Related Infection | 26 | 12.1 | 12.2 | signal |
| 7 | Prescribed Underdose | 33 | 11.8 | 12.0 | signal |
| 8 | Tachypnoea | 22 | 11.6 | 11.7 | signal |
| 9 | Clostridium Difficile Colitis | 16 | 10.8 | 10.8 | signal |
| 10 | Gastroenteritis Viral | 25 | 9.9 | 9.9 | signal |
| 11 | Metabolic Acidosis | 38 | 8.6 | 8.7 | signal |
| 12 | Spinal Pain | 14 | 8.5 | 8.6 | signal |
| 13 | Neutrophil Count Increased | 12 | 8.3 | 8.4 | signal |
| 14 | Pneumonia Aspiration | 27 | 7.7 | 7.8 | signal |
| 15 | Blood Urea Increased | 18 | 7.6 | 7.7 | signal |
| 16 | Pulmonary Congestion | 14 | 7.6 | 7.6 | signal |
| 17 | Multiple Organ Dysfunction Syndrome | 26 | 6.7 | 6.7 | signal |
| 18 | Hypotonia | 9 | 6.4 | 6.4 | signal |
| 19 | Obesity | 14 | 6.3 | 6.3 | signal |
| 20 | Bacteraemia | 10 | 6.1 | 6.1 | signal |
| 21 | Acute Respiratory Distress Syndrome | 15 | 6.1 | 6.1 | signal |
| 22 | Retching | 18 | 6.0 | 6.1 | signal |
| 23 | Viral Infection | 28 | 6.0 | 6.1 | signal |
| 24 | Gastroenteritis | 12 | 5.9 | 5.9 | signal |
| 25 | Vitamin D Deficiency | 8 | 5.9 | 5.9 | signal |
| 26 | Malnutrition | 9 | 5.8 | 5.8 | signal |
| 27 | Cholestasis | 15 | 5.6 | 5.6 | signal |
| 28 | Iron Deficiency Anaemia | 7 | 5.4 | 5.5 | signal |
| 29 | Myoclonus | 9 | 5.4 | 5.4 | signal |
| 30 | Hypophagia | 19 | 5.4 | 5.4 | signal |
| 31 | Shock | 17 | 5.3 | 5.3 | signal |
| 32 | Lymphocyte Count Decreased | 13 | 5.3 | 5.3 | signal |
| 33 | Rebound Effect | 8 | 5.0 | 5.1 | signal |
| 34 | Altered State Of Consciousness | 15 | 5.0 | 5.0 | signal |
| 35 | Hepatic Failure | 21 | 5.0 | 5.0 | signal |
| 36 | Encephalopathy | 17 | 5.0 | 5.0 | signal |
| 37 | Product Prescribing Error | 16 | 4.8 | 4.8 | signal |
| 38 | Prescribed Overdose | 13 | 4.8 | 4.8 | signal |
| 39 | Adrenal Insufficiency | 8 | 4.8 | 4.8 | signal |
| 40 | Coagulopathy | 11 | 4.7 | 4.7 | signal |
| 41 | Acute Hepatic Failure | 9 | 4.7 | 4.7 | signal |
| 42 | Hepatic Cytolysis | 8 | 4.7 | 4.7 | signal |
| 43 | Ileus | 8 | 4.6 | 4.7 | signal |
| 44 | Secretion Discharge | 8 | 4.6 | 4.6 | signal |
| 45 | Product Use Complaint | 10 | 4.6 | 4.6 | signal |
| 46 | Blood Bilirubin Increased | 17 | 4.5 | 4.5 | signal |
| 47 | Supraventricular Tachycardia | 6 | 4.5 | 4.5 | signal |
| 48 | Respiratory Tract Infection | 16 | 4.4 | 4.4 | signal |
| 49 | Feeding Disorder | 12 | 4.3 | 4.3 | signal |
| 50 | Hypersomnia | 17 | 4.2 | 4.3 | signal |
| 51 | Bacterial Infection | 11 | 4.2 | 4.2 | signal |
| 52 | Febrile Neutropenia | 39 | 4.2 | 4.3 | signal |
| 53 | Hyperbilirubinaemia | 6 | 4.2 | 4.2 | signal |
| 54 | Blood Creatine Phosphokinase Increased | 17 | 4.2 | 4.2 | signal |
| 55 | Hyperglycaemia | 21 | 4.1 | 4.2 | signal |
| 56 | Respiratory Failure | 42 | 4.1 | 4.2 | signal |
| 57 | Hepatic Function Abnormal | 21 | 4.0 | 4.1 | signal |
| 58 | Cardiogenic Shock | 8 | 4.0 | 4.0 | signal |
| 59 | Rhabdomyolysis | 23 | 3.9 | 4.0 | signal |
| 60 | Respiratory Distress | 15 | 3.9 | 3.9 | signal |
| 61 | Insurance Issue | 8 | 3.8 | 3.9 | signal |
| 62 | Skin Infection | 6 | 3.8 | 3.8 | signal |
| 63 | Personality Change | 5 | 3.8 | 3.8 | signal |
| 64 | Grand Mal Convulsion | 5 | 3.8 | 3.8 | signal |
| 65 | Hypocalcaemia | 10 | 3.8 | 3.8 | signal |
| 66 | Somnolence | 105 | 3.7 | 3.8 | signal |
| 67 | Poor Quality Sleep | 11 | 3.7 | 3.7 | signal |
| 68 | Abnormal Behaviour | 20 | 3.6 | 3.6 | signal |
| 69 | Respiratory Depression | 6 | 3.5 | 3.5 | signal |
| 70 | Influenza | 54 | 3.5 | 3.5 | signal |
| 71 | Jaundice | 13 | 3.4 | 3.5 | signal |
| 72 | Proteinuria | 9 | 3.4 | 3.4 | signal |
| 73 | Dyskinesia | 19 | 3.3 | 3.4 | signal |
| 74 | Therapy Partial Responder | 7 | 3.3 | 3.3 | signal |
| 75 | Pancreatitis | 24 | 3.2 | 3.3 | signal |
| 76 | Femur Fracture | 14 | 3.2 | 3.2 | signal |
| 77 | Pancytopenia | 25 | 3.2 | 3.2 | signal |
| 78 | Agitation | 32 | 3.1 | 3.1 | signal |
| 79 | Hospitalisation | 66 | 3.1 | 3.1 | signal |
| 80 | Appendicitis | 4 | 3.1 | 3.1 | no signal |
| 81 | Blood Test Abnormal | 6 | 3.1 | 3.1 | signal |
| 82 | Underdose | 31 | 3.0 | 3.1 | signal |
| 83 | Electrocardiogram Qt Prolonged | 15 | 3.0 | 3.0 | signal |
| 84 | International Normalised Ratio Increased | 12 | 3.0 | 3.0 | signal |
| 85 | Nervous System Disorder | 13 | 3.0 | 3.0 | signal |
| 86 | Therapy Change | 4 | 3.0 | 3.0 | no signal |
| 87 | Hyperthyroidism | 6 | 3.0 | 3.0 | signal |
| 88 | Affect Lability | 4 | 3.0 | 3.0 | no signal |
| 89 | Aggression | 20 | 2.8 | 2.9 | signal |
| 90 | Hypothermia | 4 | 2.8 | 2.8 | no signal |
| 91 | Initial Insomnia | 4 | 2.8 | 2.8 | no signal |
| 92 | Product Dose Omission Issue | 110 | 2.8 | 2.8 | signal |
| 93 | Peritonitis | 8 | 2.8 | 2.8 | signal |
| 94 | Covid-19 | 67 | 2.7 | 2.7 | signal |
| 95 | Complication Associated With Device | 5 | 2.7 | 2.7 | no signal |
| 96 | Lactic Acidosis | 12 | 2.7 | 2.7 | signal |
| 97 | Pharyngitis Streptococcal | 4 | 2.6 | 2.6 | no signal |
| 98 | Product Dispensing Error | 8 | 2.6 | 2.6 | signal |
| 99 | Drug Level Increased | 6 | 2.6 | 2.6 | signal |
| 100 | Irritability | 21 | 2.5 | 2.5 | signal |
| 101 | Sedation | 9 | 2.5 | 2.5 | signal |
| 102 | Bone Marrow Failure | 7 | 2.4 | 2.4 | signal |
| 103 | Multi-organ Failure | 6 | 2.4 | 2.4 | no signal |
| 104 | Laboratory Test Abnormal | 10 | 2.4 | 2.4 | signal |
| 105 | Intentional Dose Omission | 9 | 2.4 | 2.4 | signal |
| 106 | Convulsion | 19 | 2.3 | 2.3 | signal |
| 107 | Abortion Induced | 3 | 2.3 | 2.3 | no signal |
| 108 | Posterior Reversible Encephalopathy Syndrome | 3 | 2.3 | 2.3 | no signal |
| 109 | Thrombotic Microangiopathy | 3 | 2.2 | 2.2 | no signal |
| 110 | Eye Irritation | 17 | 2.2 | 2.2 | signal |
| 111 | Psychomotor Hyperactivity | 5 | 2.1 | 2.1 | no signal |
| 112 | Diabetes Mellitus Inadequate Control | 5 | 2.0 | 2.0 | no signal |
| 113 | Hepatocellular Injury | 4 | 2.0 | 2.0 | no signal |
| 114 | Application Site Pain | 6 | 1.9 | 1.9 | no signal |
| 115 | Anger | 9 | 1.9 | 1.9 | no signal |
| 116 | Muscle Spasticity | 3 | 1.7 | 1.7 | no signal |
| 117 | Cytomegalovirus Infection | 4 | 1.7 | 1.7 | no signal |
| 118 | Overdose | 51 | 1.7 | 1.7 | no signal |
| 119 | Diabetic Ketoacidosis | 5 | 1.5 | 1.5 | no signal |
| 120 | Device Breakage | 8 | 1.5 | 1.5 | no signal |
| 121 | Product Preparation Error | 3 | 1.0 | 1.0 | no signal |
| 122 | Tardive Dyskinesia | 3 | 0.8 | 0.8 | no signal |
| 123 | Device Leakage | 4 | 0.7 | 0.7 | no signal |
| 124 | Drug Dose Omission By Device | 7 | 0.7 | 0.7 | no signal |